LIS LIS Technologies Inc S-1/A amended IPO prospectus section summaries
An AI model summarized each section of the prospectus on its own; the summary was written from these. They are longer and less edited than the summary, and the filing on SEC is the authority.
Cover page
LIS Technologies Inc. — Form S-1 Amendment No. 2 cover
LIS Technologies filed Amendment No. 2 to its Form S-1 on November 17, 2026, for a proposed firm-commitment initial public offering. The preliminary price range is $5.00–$7.00 per share; the final offering price has not been determined. There was no prior public market for the common shares.
| Offering terms | Proposed offering |
|---|---|
| Base shares offered | 3.1 million |
| Assumed price per share | $6.00 |
| Estimated gross proceeds at assumed price, before underwriting compensation and expenses | Approximately $18.6 million |
| Underwriter over-allotment option | Up to 465,000 additional shares, exercisable for 30 days |
| Estimated additional proceeds if option is fully exercised, before expenses | Approximately $2.5947 million |
Underwriters receive a 6.5% discount, a 1.15% non-accountable expense allowance, and reimbursement of certain expenses. They will also receive warrants to purchase shares equal to 7% of the shares sold, including any over-allotment shares, at an exercise price equal to 115% of the IPO price. If the over-allotment option is exercised in full, the filing estimates total underwriting discounts of approximately $1.39035 million.
CEO and Chairman Jay Jiang Yu and President and co-founder Christo J. Liebenberg each expressed nonbinding interest in purchasing up to $250,000 of shares. Any insider purchases would reduce the shares available to public investors. Shares purchased by them would be subject to a 180-day lock-up and resale restrictions.
Nasdaq approval is a condition of the offering; the company says it will not proceed if its listing application is not approved. LIS Technologies identifies as both an emerging growth company and a smaller reporting company and may therefore use reduced public-company reporting requirements. The prospectus characterizes an investment in the shares as speculative and high-risk.
Prospectus summary
Business and development status
LIS Technologies is a pre-revenue, early-stage uranium-enrichment company developing its proprietary laser-based CRISLA process. It has not begun commercial production or sales, has generated no revenue since inception, and recorded cumulative net losses of $65.419 million from inception through July 31, 2026. It does not expect uranium-product revenue in the foreseeable future and expects significant losses to continue. Share amounts in the prospectus reflect a 1-for-2.5 reverse stock split effective April 22, 2024.
CRISLA selectively excites uranium isotopes with lasers. The technology was experimentally validated in the early 1990s but was not developed commercially, principally because of geopolitical, market and financing conditions. LIS says its approach uses a different UF₆ vibrational mode and continuous-wave lasers, which it believes could offer operating and cost advantages. These remain prospective claims: LIS has not demonstrated commercial-scale performance, reliability, scalability or cost efficiency. Earlier laser-enrichment programs also failed to reach commercial operation; U.S. AVLIS reportedly reached TRL 6–7 after more than $2 billion of investment over approximately 20 years, but was not commercialized.
LIS has begun laboratory-scale Phase 1 testing and optimization and experimental testing of Phase 2 industrial-scale equipment, including converting an industrial CO₂ laser to a CO laser. Its staged plans are:
| Development target | Timing and planned scale |
|---|---|
| Phase 1: re-demonstrate and optimize CRISLA | Expected through 2027 |
| Phase 2: industrial-scale equipment and begin enrichment | Expected through 2028 |
| Phase 3: site preparation, licensing, facility design and pilot plant | Targeted operational readiness around 2030; approximately 50 metric tons of LEU and 0.5 million SWU annually |
| Phase 4: commercial LEU-3 facility | Operations contemplated around 2033; approximately 500 metric tons of LEU and 5.0 million SWU annually |
The planned Oak Ridge commercial facility is at LIST Island, a company-owned 206-acre brownfield site. LIS describes initial commercial enrichment capacity of approximately 3.0 million SWU annually, potentially expandable to 5.0 million; together with the pilot plant, planned aggregate capacity could reach approximately 5.5 million SWU annually. These are targets, not demonstrated or committed capacity. Phase 3 work remains preparatory, and Phase 4 activities have not begun. LIS also owns a 38,000-square-foot building undergoing renovation for Phase 2 and leases office and laboratory space, including space from related party NANO Nuclear.
Market opportunity, funding and partnerships
LIS cites UxC projections of U.S. SWU requirements in 2045 ranging from approximately 11 million in a low case to 39 million in a high-growth case, against current domestic enrichment capacity below 5 million SWU annually—an estimated annual gap of approximately 6–35 million SWU. The U.S. reactor fleet is nearly 100 reactors, including three being restarted; U.S. nuclear capacity was approximately 99 GWe as of March 31, 2026, with UxC projecting 114–135 GWe by 2045. LIS’s opportunity thesis also reflects demand for LEU and potential HALEU, U.S. efforts to diversify supply after 2024 Russian uranium import restrictions, and a 2025 U.S. policy goal to quadruple nuclear power capacity by 2050.
Funding remains a major constraint. Existing cash and other available capital support only a scaled, prioritized subset of Phase 1 and Phase 2; completing those phases and advancing through licensing, construction and operation will require substantial additional capital. LIS expects to pursue equity or debt financing, strategic investment and commercial arrangements, but financing may not be available on acceptable terms or at all. In January 2026, it announced a goal to invest $1.38 billion in a future commercial-scale facility at the historic K-25 site.
LIS is one of six participants in a ten-year DOE multiple-award IDIQ contract for potential LEU-related work. DOE pays only for work under individual task orders; the contract does not fund facility construction or operation, and LIS does not currently rely on it for funding. The DOE has approximately $3.4 billion in appropriated LEU/HALEU funding and announced $2.7 billion in task-order awards to three higher-TRL companies in January 2026. LIS’s fully funded Air Force Phase I SBIR contract, awarded January 15, 2025, totals $74,866 for research and reporting, subject to acceptance; it provides no commitment to future phases or procurement. LIS has been offered and is pursuing state and local incentives estimated at more than $200 million over their life, but most are conditional and had not been received as of the prospectus date.
NANO Nuclear, which shares ownership and management connections with LIS, invested approximately $2.0 million in LIS, including an August 2024 investment for 2,666,667 common shares. A September 2026 collaboration agreement outlines possible UF₆ feedstock supply, enriched and deconverted product, cost sharing and jointly developed IP. Commercial terms remain subject to a definitive agreement that has not been signed; the parties are not operating an integrated fuel supply chain, and related downstream work is exploratory. CEO and Chairman Jay Jiang Yu also chairs NANO Nuclear and is a material stockholder, creating related-party considerations. LIS acquired CRISLA Inc., developer of the CRISLA patent, for aggregate consideration of $1.245434 million in August 2023.
Key execution risks and reporting status
Commercialization depends on technical scale-up, substantial additional capital, NRC and other approvals, construction and customer demand. Tennessee issued a radiological-material license in December 2025 for certain laboratory activities; a UF₆ cylinder arrived in October 2026, with experiments expected by year-end. The NRC approved LIS’s security-procedures plan in October 2026, but it becomes active only after a successful operational-readiness review. A separate NRC license is still required to construct and operate a commercial enrichment facility.
Risks include lengthy licensing and environmental reviews; nuclear safety, security, safeguards and export-control requirements; technical challenges involving component durability, contamination, thermal management, vibration and optical alignment; supply-chain concentration; cost overruns and delays; and uncertain timing of utility procurement, government support and reactor deployment. Potential HALEU production, medical or stable-isotope applications, facility expansion and acquisitions remain conditional possibilities, not committed plans.
LIS qualifies as both an emerging growth company and a smaller reporting company. It has not opted out of the JOBS Act extended transition period for new accounting standards and may use reduced disclosure, including exemption from auditor attestation of internal controls. EGC status ends upon specified revenue, debt, market-value or time thresholds, including annual gross revenue above $1.235 billion, issuance of more than $1.0 billion of non-convertible debt over three years, or non-affiliate market value above $700 million at the specified measurement date. The company also cautions that its shares may be volatile and future equity or convertible-security sales could pressure the stock price.
The offering
Proposed offering
LIS proposes to sell 3.100 million common shares at an assumed IPO price of $6.00 per share. Underwriters have a 30-day option to purchase an additional 465,000 shares, bringing the total offering to 3.565 million shares if fully exercised.
| Offering scenario | Shares sold | Estimated net proceeds |
|---|---|---|
| Base offering | 3.100M | $16.4M |
| Full over-allotment | 3.565M | $19.0M |
Net proceeds are estimated after underwriting discounts and offering expenses. The company intends to use them for uranium-enrichment product and technology research and development, including laser and separator design and development; characterization and preparation of the LIST Island site; construction, systems testing and integration; operational scoping studies; marketing and business development; and working capital and general corporate purposes, including regulatory compliance, intellectual-property protection, and hiring employees and contractors.
Shares and potential dilution
As of November 13, 2026, 71.711M shares were outstanding. The count is expected to be 74.811M after the base offering, or 75.276M if the over-allotment option is fully exercised. The pre-offering count includes 2.250M shares issued to Starfire Industries that are subject to performance milestones and may be forfeited or canceled if those milestones are not met.
The company’s disclosed securities and reserved shares produce the following gross fully diluted share count for the base offering, with no option- or warrant-exercise proceeds netted:
| Fully diluted share count (base offering) | Shares |
|---|---|
| Post-offering shares, including 71.711M pre-offering shares and 3.100M IPO shares | 74.811M |
| Representative’s warrant | +0.217M |
| 2026 Plan shares reserved for future issuance | +0.98371M |
| Outstanding 2026 Plan RSUs | +5.115M |
| Outstanding 2023 Stock Option Plan options | +6.1680M |
| Outstanding options outside the 2023 Plan | +17.672M |
| Total | 104.97M |
The total includes reserved plan shares and underlying awards; the prospectus assumes no option or warrant exercise.
Underwriting arrangements and other considerations
Titan Partners Securities LLC, the underwriters’ representative, will receive a warrant covering 217,000 shares, equal to 7% of shares sold in the base offering. It has customary cashless-exercise provisions and is exercisable from the first day of the seventh month after closing through the fifth anniversary at 115% of the IPO price—approximately $6.90 per share at the assumed offering price.
Proceeding with the offering is conditioned on Nasdaq listing approval, and LIS cautions that a trading market may not develop. Its proposed Nasdaq symbol is LIS. The company agreed to a 180-day standstill restricting specified securities offerings and related transactions without Titan’s consent, subject to exceptions. Executives, directors, and affiliates are subject to 180-day lockups; non-insider holders of at least 0.5% are subject to leak-out restrictions for 90–180 days.
CEO and Chairman Jay Jiang Yu and President and co-founder Christo J. Liebenberg each indicated nonbinding interest in purchasing up to $250,000 of IPO shares. Any such purchases would reduce shares available to the public; purchased shares would remain subject to lockup and Rule 144 resale limitations. The filing characterizes an investment in the offering as speculative and high-risk.
Prospectus summary
LIS — Prospectus Summary
LIS reported operating losses in every period presented, with no revenue presented. In the nine months ended July 31, 2026, higher operating expenses drove a substantially wider operating loss. The quarterly net loss was narrower year over year, primarily because the prior-year quarter included a fair-value loss on acquisition consideration payable in equity.
Results
| $ millions, except per-share amounts | Q3 FY2026 | Q3 FY2025 | 9M FY2026 | 9M FY2025 |
|---|---|---|---|---|
| General and administrative expense | $2.5789 | $1.5045 | $15.7827 | $9.5604 |
| Research and development expense | 1.9403 | 1.5646 | 11.4461 | 2.5779 |
| Operating loss | (4.5192) | (3.0691) | (27.2288) | (12.1383) |
| Other income | 0.2204 | 0.5365 | 0.7408 | 1.0904 |
| Net loss | (4.2989) | (6.3726) | (29.6880) | (18.2478) |
| Basic and diluted loss per share | — | — | $0.47 | $0.35 |
| $ millions | FY2025 | FY2024 |
|---|---|---|
| General and administrative expense | $11.8782 | $10.2191 |
| Research and development expense | 3.8736 | 1.4240 |
| Operating loss | (15.7518) | (11.6431) |
| Other income | 1.4125 | 0.0642 |
| Net loss | (21.5393) | (13.6807) |
A fair-value loss on acquisition consideration payable in equity was $3.8400 million in Q3 FY2025 and none in Q3 FY2026. For 9M FY2026, the charge was $3.2000 million, down from $7.2000 million in 9M FY2025; for FY2025, it was $7.2000 million versus $2.1018 million in FY2024.
Balance sheet
| $ millions | July 31, 2026 | October 31, 2025 |
|---|---|---|
| Total assets | $50.9194 | $37.7462 |
| Total stockholders’ equity | 32.3565 | 26.1636 |
| Total liabilities | 18.5629 | 11.5826 |
| Cash | 18.7917 | 33.2293 |
| Property, plant and equipment | 28.9890 | 2.0258 |
| Goodwill | None reported | None reported |
| Other intangible assets, total | 1.6795 | 1.2406 |
| └ In-process research and development | 1.6795 | 1.2406 |
| Acquisition consideration payable in equity | 12.8000 | 9.6000 |
Cash flow and financing
| $ millions | 9M FY2026 | 9M FY2025 | FY2025 | FY2024 |
|---|---|---|---|---|
| Operating cash flow | (14.8194) | (5.4242) | (8.3450) | (3.1982) |
| Cash purchases of property, plant and equipment | 24.8759 | 1.0749 | 1.8220 | 0.2039 |
During 9M FY2026, financing provided $25.2577 million, including $24.2267 million from common-stock issuances and $1.1790 million from option exercises. Cash declined by $14.4376 million over the period. Of FY2026 property, plant and equipment additions, $2.0872 million was included in accounts payable and accrued liabilities.
Equity and share information
| Shares, millions | Period start | Period end |
|---|---|---|
| Common shares outstanding, 9M FY2026 | 56.5751 (October 31, 2025) | 68.3114 (July 31, 2026) |
| Common shares outstanding, 9M FY2025 | 40.0587 (October 31, 2024) | 56.5751 (July 31, 2025) |
The July 31, 2026 common-share count includes 2.2500 million unvested shares subject to forfeiture. Weighted-average diluted shares were 62.5566 million in 9M FY2026 versus 52.1881 million in 9M FY2025. Equity-based compensation expense was $10.4752 million versus $5.3471 million, respectively; FY2025 expense was $5.3471 million versus $8.7944 million in FY2024.
Risk factors
Business, financing and commercialization risks
LIS, founded in December 2021, is a pre-revenue uranium-enrichment company. It has not generated revenue and does not expect uranium-product or enrichment-services revenue until it completes development, licensing, construction and commercialization—a process expected to take years. For the nine months ended July 31, 2026, LIS reported a $29.688 million net loss, $14.819 million of negative operating cash flow and a $65.419 million accumulated deficit. It expects losses and negative cash flows to continue and increase as it funds research and development, engineering, regulatory work, personnel and facilities.
The company has historically relied on equity financing and expects to need substantial additional capital, potentially hundreds of millions of dollars beyond offering proceeds. In January 2026, it announced a goal to invest $1.38 billion in a future flagship facility at Oak Ridge’s historic K-25 site. Capital needs could exceed estimates because of technical difficulties, scope changes, inflation, supply constraints or regulation. Financing may be unavailable or costly or restrictive: equity could dilute shareholders, debt could add interest, repayment obligations and covenants, while partnerships or licensing could require sharing technology or intellectual-property rights. Grants and government support are uncertain and may carry conditions or IP rights.
Technology, facilities and execution
LIS’s CRISLA laser-isotope-separation process was assessed at TRL 4 in March 2025, meaning validated at laboratory scale; the assessment is voluntary and does not assure successful scale-up. The technology has not been demonstrated at commercial scale or shown to meet required reliability, throughput, efficiency, product-quality and cost targets. LIS plans systems engineering, integration and testing at its Oak Ridge demonstration facility to reproduce and optimize enrichment results achieved in 1993. Scale-up could expose problems with component durability, contamination, thermal management, vibration, optical alignment, manufacturability and sustained separation performance, requiring redesign, added spending or delays. Cost-per-SWU projections rely on assumptions about capital and operating costs, financing and commercialization timing that may prove materially inaccurate.
The roadmap targets TRL 5 in 2025–2027, TRL 6–7 in 2025–2028, pilot-plant readiness around 2030 and an LEU-3 commercial facility around 2033. The pilot is planned for approximately 50 metric tons of LEU and 0.5 million SWU annually. LEU-3 is planned for approximately 500 metric tons of LEU and 5.0 million SWU annually; another stated plan is to begin at 3.0 million SWU and potentially expand to 5.0 million. These are targets, not assured outcomes. Concurrent phases increase capital needs and management complexity, and setbacks in one phase could affect later development.
Regulatory, market and supply-chain exposure
LEU-3 depends on NRC and other governmental approvals. LIS anticipates submitting its NRC application in Q1 2027 after technical, environmental and regulatory work; it estimates review could take about 18 months after submission, but timing and outcome are uncertain. Regulators could request substantial additional information or design changes, impose conditions, find an application incomplete or deny it. Required permits and authorizations also cover environmental and land-use matters, safeguards, security, transportation and export controls; delays, added conditions, violations or incidents could raise costs, restrict operations or prevent commercialization.
Under Atomic Energy Act Section 57(b) and 10 CFR Part 810, DOE authorization may be required for providing enrichment technology or assistance to foreign parties or foreign nationals. Enrichment-equipment exports require NRC licensing under 10 CFR Part 110. Technology may be classified or treated as Restricted Data, requiring facility and personnel clearances, secure systems and controls on access. These requirements could constrain hiring, international collaboration and operations. LIS disclosed a voluntary self-disclosure to NNSA in September 2026; export-control violations could result in fines, restricted privileges, increased oversight and reputational harm.
Commercialization depends on durable demand for LEU and potentially LEU+ and HALEU, which is exposed to reactor construction, restarts, utility procurement cycles, inventories, policy and geopolitics. Nuclear-fuel qualification and contracting take time; expressions of interest, MOUs and letters of intent may not become binding offtake. LIS may incur costs before securing customers or be unable to supply when demand arises. Competition from established centrifuge suppliers and alternative technologies, changing fuel strategies, secondary supply and inventory use could reduce demand, market share or margins. The filing contrasts LIS’s guaranteed DOE LEU Acquisition Program award of up to $2 million, payable against milestones, with $900 million awards to each of three higher-TRL companies; LIS cautions that the technologies and TRL assessments may not be directly comparable, but perceived maturity gaps could affect investor confidence and capital access.
Operations depend on a concentrated, multistage supply chain, including uranium conversion and UF₆ feedstock, reagents, cylinders, specialized equipment, transport and handling. Supplier shortages, outages, quality issues, trade restrictions, logistics constraints or price volatility could delay projects, raise costs or constrain production.
Partners, people, safety and legal risks
LIS relies partly on related-party NANO Nuclear for strategic, technical, engineering-integration and commercial support. NANO invested $2 million in August 2024 for 2,666,667 LIS shares. A Joint Collaboration Agreement restated on September 8, 2026 provides a framework for NANO to work toward conversion facilities and UF₆ feedstock and LIS to provide enriched and deconverted UF₆, with reciprocal preferred-customer status. However, no definitive proceeds-sharing agreement had been signed as of the prospectus date; pricing, profit split, costs, responsibilities and timing remain to be negotiated. Failure to agree, a change in the relationship or loss of NANO support could mean lost expected sales participation, added costs or delays. Suppliers and other partners may also underperform, terminate arrangements or dispute scope, pricing or IP.
Execution depends on senior leaders and scarce specialized talent. CEO and Chairman Jay Jiang Yu beneficially owned approximately 25.92% of common stock as of November 13, 2026 and is expected to own approximately 25.00% after the offering, assuming no over-allotment. His roles at NANO Nuclear and Human Continuum may create competing demands and conflicts; he is expected to devote at least 40 hours weekly to NANO and about two hours to Human Continuum. Loss of key personnel or inability to recruit and retain qualified staff could impair development.
Handling UF₆, hydrogen fluoride and other hazardous, radioactive, toxic or corrosive materials entails substantial safety, environmental, waste-management and emergency obligations. Accidents, cyberattacks, natural disasters or security incidents could interrupt operations, cause injury or contamination, and result in remediation, liability, fines, litigation, permit delays or shutdowns. LIS says its disaster-recovery plans may be inadequate for a serious event. It currently lacks specialized nuclear/radiological and environmental/pollution liability insurance, as well as key-person life and business-interruption insurance; available coverage may be costly, limited or exclude nuclear and environmental losses. Required financial assurance for construction, operations and decommissioning may also tie up capital.
LIS identifies one owned patent, the CRISLA Patent, USPTO No. 10,319,486, and relies on patents, trade secrets and know-how. IP may be challenged, misappropriated, independently developed by competitors or subject to disputes with collaborators over ownership and rights. Infringement claims, even if meritless, could require costly defense, licenses, damages or operational changes. The company also faces litigation, tax, anti-bribery, AML and indemnification exposures.
Public-company and shareholder risks
Before becoming public, LIS had limited accounting staff and segregation of duties and had not established an effective public-company control environment or internal audit function. It may not complete control documentation, testing and remediation on time. The IPO adds reporting, governance, insurance and staffing costs and management demands. LIS elected the extended transition period for new accounting standards, potentially reducing comparability. It expects no dividends for the foreseeable future.
Yu and President/co-founder Christo J. Liebenberg each indicated nonbinding interest in buying up to $250,000 of IPO shares. Shares held by executives and other holders are subject to lock-ups or leak-out limits; sales or perceived future availability could pressure the stock. Immediately after the offering, shares outstanding are expected to be 74.811408 million, or 75.276408 million with full exercise of the over-allotment option. At the assumed $6.00 per share IPO price, the sale of 3.1 million shares is expected to cause $5.31 per share of immediate dilution to IPO investors, before any over-allotment. Future equity issuances, options or warrants could add dilution. Management has broad discretion over offering proceeds.
No active trading market existed before the IPO, and one may not develop or persist. The stock may be volatile, future sales may depress its price, and failure to meet Nasdaq listing requirements could impair liquidity. Nevada anti-takeover provisions and forum-selection clauses may deter transactions or limit where shareholders can bring specified claims; enforceability is uncertain, and the clauses may raise litigation costs or restrict shareholders’ choice of forum.
Cautionary note regarding forward looking statem
Cautionary Note Regarding Forward-Looking Statements
The company is an early-stage, pre-revenue uranium-enrichment business. Its business model and commercialization strategy are still being developed and have not been validated. Commercial success depends on re-demonstrating and optimizing CRISLA enrichment; developing industrial-scale equipment; designing and financing the laser-enrichment system; and completing, commissioning, and operating the Pilot Plant and LEU-3 Facility so it can produce and sell enriched uranium products (EUPs) to utilities and advanced-reactor companies.
The company expects to need substantial additional capital. Financing may not be available on acceptable terms—or at all—and its estimates of expenses, future revenue, capital requirements, and financing availability may prove inaccurate. Key risks include technical or scale-up failure, inability to commercialize or sell EUPs, and unanticipated NRC or other regulatory requirements that could delay or constrain operations.
Protecting classified technology is critical: unauthorized disclosure could result in suspension or termination of the facility security clearance, while delays in obtaining or maintaining personnel clearances could impede operations. Other risks include cybersecurity or IT disruptions, data breaches or implementation failures, and inability to obtain and enforce adequate intellectual-property protection.
Forward-looking statements are based on estimates and assumptions as of the prospectus date and are subject to known and unknown risks; actual results may differ materially. The company generally disclaims any obligation to update or revise these statements except as required by law.
Use of proceeds
Use of IPO Proceeds
The company estimates net IPO proceeds of approximately $16.4 million, assuming an offering price of $6.00 per share (the midpoint of the offering range), excluding the underwriters’ over-allotment option and after estimated offering expenses.
| Planned use | Allocation | Estimated amount |
|---|---|---|
| Uranium-enrichment research and development | 67.5% | Approximately $11.07 million |
| Marketing, promotion and business development | 12.5% | Approximately $2.05 million |
| Working capital and general corporate purposes | 20.0% | Approximately $3.28 million |
R&D spending is expected to support laser and separator technologies; characterization, preparation and construction of the LIST Island site; system testing and integration; and operational planning. Working capital and general corporate purposes include regulatory compliance, intellectual-property protection, hiring and contractor costs.
The estimates are sensitive to the offering price: each $1.00 change in the assumed price would change net proceeds by approximately $2.9 million, assuming the number of shares offered remains unchanged. Management may reallocate proceeds and has broad discretion over their use and timing. Possible uses also include acquisitions, licenses or investments in complementary businesses, although the company has no current commitments for these purposes. Until deployed, proceeds are expected to be invested in capital-preservation instruments, including short-term investment-grade interest-bearing instruments and U.S. government securities.
Funding Needs and Risks
The company is early-stage, has a limited operating history and has adopted the legacy CRISLA laser-enrichment process, making its prospects and future expenditures difficult to assess. Developing a commercial laser-enrichment facility is expected to cost substantially more than the IPO proceeds, so the company will require significant additional capital. Potential sources include equity or equity-linked offerings, loans, commercial collaborations such as licenses or joint ventures, and potentially government grants. There is no assurance that additional funding can be raised successfully or on time; failure to obtain needed capital could cause the company to fail.
Dividend policy
LIS has never declared or paid cash dividends and does not expect to do so in the foreseeable future. It intends to retain any future earnings to fund business development and growth. Any future dividend would be at the board’s discretion, taking into account earnings, capital needs, financial condition, and other relevant factors.
Capitalization
Capitalization and IPO pro forma
As of July 31, 2026, the company had $18.792M of cash, $18.563M of total liabilities, and $32.356M of stockholders’ equity and total capitalization. The pro forma columns reflect, first, shares issued upon post-July 31 option exercises and, second, the assumed IPO.
| Capitalization item | Actual, July 31, 2026 | Pro forma after option exercises | Pro forma as adjusted for IPO |
|---|---|---|---|
| Cash | $18.792M | $21.357M | $37.766M |
| Total liabilities | $18.563M | $18.563M | $18.563M |
| Stockholders’ equity / total capitalization | $32.356M | $34.921M | $51.331M |
| Shares outstanding | 68.311M | 71.711M | 74.811M |
The option-exercise pro forma includes 3.3M shares issued after July 31. The IPO-adjusted case assumes the sale of 3.1M shares at $6.00 per share, without an underwriters’ over-allotment. It deducts approximately $1.423M of underwriting discounts and allowance and $0.768M of estimated offering expenses, producing approximately $16.409M of net proceeds above the option-exercise pro forma. The actual July 31 share count includes 2.25M Starfire Industries shares subject to milestone-based vesting and forfeiture. The company also reported 71.711M shares outstanding as of November 13, 2026, before the offering.
Potential share overhang
The following potential shares as of November 13, 2026 are excluded from the 74.811M post-offering share count:
| Potential shares | Amount |
|---|---|
| Shares underlying Representative’s Warrant | 0.217M |
| Shares reserved for future issuance under the 2026 Plan | 0.984M |
| Shares underlying outstanding 2026 Plan RSUs | 5.115M |
| Shares underlying outstanding 2023 Plan options | 6.168M |
| Shares underlying options outside the 2023 Plan | 17.672M |
| Total potential shares excluded | 30.156M |
Adding these shares gross to the stated post-offering count would yield 104.967M shares. This is a gross addition, not a netted or conventional diluted share count.
Offering sensitivity
For each $1.00 change from the assumed $6.00 IPO price, adjusted cash, additional paid-in capital, equity, and capitalization would change by approximately $2.9M. For each 100,000-share change in offering size, cash, equity, and capitalization would change by approximately $0.6M. Final proceeds and capitalization depend on the IPO price and terms.
Dilution
IPO proceeds and dilution
Assuming an offering price of $6.00 per share, the company plans to sell 3.1 million shares, generating $18.6 million of gross proceeds before underwriting discounts and estimated offering expenses.
As of July 31, 2026, historical net tangible book value (NTBV) was $30.529 million, or $0.46 per share, based on 66.061 million shares. That historical share count excludes 2.25 million issued but unvested shares subject to forfeiture. After the offering and estimated expenses, pro forma adjusted NTBV would be $49.6 million, or $0.68 per share. The filing states that existing holders’ NTBV per share increases by $0.21, while new investors experience immediate dilution of $5.32 per share.
| Offering scenario | Shares sold | Adjusted NTBV per share | Immediate dilution per new share |
|---|---|---|---|
| No over-allotment | 3.1 million | $0.68 | $5.32 |
| Full over-allotment | 3.565 million | $0.72 | $5.28 |
Without over-allotment, each $1.00 change in the offering price would change adjusted NTBV by approximately $2.9 million, or $0.04 per share, and change new-investor dilution by approximately $0.96 per share. Additional dilution could result from stock options.
Post-offering ownership and consideration
| Holder group | Shares without over-allotment | Ownership | Stated consideration |
|---|---|---|---|
| Existing holders | 71.711 million | 96% | $75.330 million ($1.05 per share) |
| New investors | 3.1 million | 4% | $18.6 million ($6.00 per share) |
| Total | 74.811 million | 100% | — |
The post-offering share count includes 2.25 million performance-based shares that are subject to forfeiture if specified milestones are not met. With full exercise of the over-allotment option, new investors would hold approximately 5% and existing holders approximately 95%.
Fully diluted share count
The filing’s 74.811 million post-offering shares outstanding without over-allotment exclude the following potential shares:
| Excluded potential shares | Shares |
|---|---|
| Representative’s warrant | 217,000 |
| 2026 Plan shares reserved for future issuance | 983,711 |
| Outstanding 2026 Plan RSUs | 5.115 million |
| Outstanding options under the 2023 Stock Option Plan | 6.168007 million |
| Outstanding options outside the 2023 Stock Option Plan | 17.672 million |
| Total excluded potential shares | 30.155718 million |
Adding these exclusions produces a gross potential total of 104.967126 million shares without over-allotment. This is not an exercise-price-adjusted or treasury-stock-method diluted share count; the filing does not provide such a figure.
Management's discussion and analysis
Business status and development program
LIS is a pre-revenue uranium-enrichment developer pursuing its proprietary laser-based CRISLA process. It has generated no revenue through July 31, 2026, and expects no meaningful revenue for several years, if at all, while it develops the technology, obtains regulatory approvals, and prepares for commercialization. Accumulated net losses were $65.419M from inception on December 31, 2021 through July 31, 2026.
Development Phases 1–3 are proceeding concurrently; Phase 4 has not started. Phase 1 laboratory-scale testing and optimization and Phase 2 industrial-scale equipment and enrichment testing both began in 2025 and are expected to continue through 2027 and 2028, respectively. Phase 2 includes converting an industrial CO₂ laser to a CO laser and renovating the 150 Americus Property. Phase 3 work remains preparatory: site, environmental and licensing work; conceptual design of the LEU-3 Facility; and Pilot Plant planning. No Phase 3 research or testing, or LEU-3 construction, has begun. Phase 4 construction is planned from 2028 onward.
The Oak Ridge Test Demonstration Facility received a Tennessee Radiological Material License in December 2025 for specified laboratory-scale activities. A UF₆ cylinder arrived in October 2026, and experiments were expected to begin before year-end. The NRC approved the facility’s Security Plan for Protection of Classified Matter in October 2026, but it will not become active until a successful operational readiness review. LIS anticipates submitting its LEU-3 license application in Q1 2027; management estimates NRC review could take about 18 months, with uncertain timing and outcome. Construction and commercial operation require NRC licensing.
| Planned facility | Target timing | Planned annual capacity |
|---|---|---|
| Pilot Plant | Operational readiness around 2030 | Approximately 50 metric tons of LEU and 0.5 million SWU |
| LEU-3 Facility, LIST Island | Operations targeted around 2033 | Approximately 3.0 million SWU, potentially expandable to 5.0 million SWU |
| Combined, if both facilities reach planned capacity | — | Approximately 5.5 million SWU |
These schedules and capacity estimates are not assured and depend on technology performance, demand, financing, approvals, and construction. LIS owns the 206-acre LIST Island site in Oak Ridge.
Results and spending
| Expense / income item | Q3 FY2026 | Q3 FY2025 | 9M FY2026 | 9M FY2025 |
|---|---|---|---|---|
| Research and development | $1.940M | $1.565M | $11.446M | $2.578M |
| — CRISLA laboratory expense | $1.708M | $0.376M | $10.073M | $0.619M |
| — Other proprietary processes and systems laboratory expense | $0.233M | $1.189M | $1.374M | $1.959M |
| General and administrative | $2.579M | $1.504M | $15.783M | $9.560M |
| Interest income | $0.220M | $0.355M | $0.741M | $0.835M |
Quarterly R&D rose 24%, reflecting increased internal and external technical personnel; G&A rose 71.4%, mainly from personnel, professional fees, travel, and IT costs. For 9M FY2026, R&D increased sharply as spending shifted toward CRISLA development and expanded personnel. G&A growth primarily reflected about $5M of additional payroll and consulting costs, $0.352M of higher legal, audit, and accounting fees, and other increases. Prior-year 9M income also included $0.181M of DOE task-order income and $0.075M of U.S. Air Force award income.
9M FY2026 R&D included $5.022M of equity-based compensation, versus $0.490M a year earlier: approximately $3.0M related to 750,000 common shares issued to Starfire Industries and immediately vested, and approximately $2.022M for shares issued to consultants. An additional 2.25M shares are issuable to Starfire upon performance milestones, are forfeitable if milestones are missed, and have not been expensed. G&A equity compensation was $5.453M versus $4.857M; no equity-based compensation was included in G&A in either Q3 quarter.
For context, FY2025 R&D was $3.874M versus $1.424M in FY2024, while G&A was $11.878M versus $10.219M. FY2025 other income included $1.157M of interest and $0.256M under Air Force and DOE contracts; FY2024 interest income was $0.064M.
Liquidity and cash flows
| Cash flow (nine months ended July 31) | 9M FY2026 | 9M FY2025 |
|---|---|---|
| Operating cash used | $14.819M | $5.4242M |
| Investing cash used | $24.876M | $1.0749M |
| Financing cash provided | $25.258M | $26.767M |
| Change in cash | $(14.438)M | $20.268M increase |
Higher R&D, regulatory and personnel costs, and office and professional fees drove increased operating cash use. Investing outflows included approximately $8M to purchase LIST Island, $6.1M for land and a building at the 150 Americus Property, and approximately $9M of year-to-date LEU-3 pre-construction, design, and development costs. FY2026 financing included $24.227M from private placements and $1.179M from option exercises, offset by $0.1480M of deferred offering costs. The prior-year period included $34.502M from private placements and $7.735M in net stock-subscription proceeds for shares not yet issued.
At July 31, 2026, cash was approximately $18.8M and working capital approximately $14.9M, down from approximately $33M and $32M, respectively, at October 31, 2025. LIS raised approximately $17M gross in a January 2026 private placement at $3.50 per share and approximately $7M in a March placement at $4.00 per share. Management estimates approximately $74M of cash requirements for the 12 months ending July 31, 2027: $18M operating expenses, $28M CRISLA laboratory expenses, $4M other-process expenses, and $24M scaled-facility development.
Under the current plan, cash is expected to fund operations only into Q1 FY2027. Management expects to seek additional equity or debt financing, strategic investment, commercial arrangements, or other capital; availability and terms are uncertain, and equity or equity-linked financing could dilute shareholders. Before considering management’s plans, the funding outlook raised substantial doubt about LIS’s ability to continue as a going concern within one year. Management concluded the doubt was alleviated because discretionary spending—including scaled-facility development and a substantial portion of CRISLA laboratory work—could be deferred or sequenced to preserve cash for at least one year of non-discretionary expenses and commitments. Estimates are reassessed quarterly.
Market opportunity and principal risks
Management points to U.S. nuclear-fuel security initiatives, including the 2024 Prohibiting Russian Uranium Imports Act (subject to exceptions and waivers), and expected growth in nuclear power. Cited UxC projections put U.S. nuclear capacity in 2045 at approximately 114 GWe in a low case and 135 GWe in a high case, compared with approximately 99 GWe operable as of March 31, 2026. Estimated 2045 U.S. enrichment needs range from approximately 11 million to 39 million SWU/year, against current domestic capacity below 5 million SWU/year—a projected supply gap of approximately 6–35 million SWU/year, depending on demand. CRISLA was experimentally validated in the early 1990s but has not been commercially deployed; the company attributes this primarily to market, geopolitical, and financing conditions rather than a finding of technical infeasibility. Its related patent issued in June 2019.
LIS has no offtake or future fuel-purchase agreements and remains several years from commercial-scale production. Key risks include technology development and scale-up, access to capital, NRC licensing delays, construction and operational readiness, uncertain customer demand, and specialized equipment availability and lead times. Operations also involve safety, environmental, physical-security, and cybersecurity risks, including UF₆ handling, potential radioactive waste, accident or sabotage exposure, and classified-information requirements. Compliance may require extensive analyses, controls, emergency plans, clearances, and added cost.
The company’s $1.680M acquired in-process R&D asset represents laser isotope-separation technology acquired in 2023. It is not amortized because management identified possible medical, semiconductor, and quantum-computing stable-isotope applications. Its indefinite-lived classification and impairment assessment depend on development progress, demonstrating enrichment results at scale, NRC review, and funding; abandonment or adverse developments could result in an impairment charge up to its carrying amount. Management reported no impairment indicators at July 31, 2026.
Business
Business overview and market opportunity
LIS is an early-stage uranium-enrichment developer with no commercial production or enriched-uranium sales. From inception on December 31, 2021 through July 31, 2026, it accumulated net losses of $65.419 million and invested approximately $10.7 million in LIST technology research and development.
The company aims to commercialize its patented CRISLA laser-based uranium-isotope separation process for conventional light-water reactors and advanced reactors, including SMRs and MMRs. LIS says historical CRISLA experiments in the early 1990s validated the process, but it was not commercialized amid unfavorable market, geopolitical and financing conditions—not because it was determined technically infeasible. Its U.S. patent issued in 2019 and was assigned to LIST in 2024. The company describes itself as the only company with U.S.-origin patented laser uranium-enrichment technology, based on its public research.
LIS cites a growing potential market for domestic enrichment. U.S. enrichment requirements projected for 2045 range from approximately 11 million to 39 million SWU, compared with current domestic capacity of less than 5 million SWU annually—a potential supply gap of approximately 6 million to 35 million SWU. The U.S. prohibition on Russian-origin LEU imports, effective August 2024 subject to exceptions and waivers, and renewed nuclear-power commitments may support demand. These market conditions do not ensure that LIS can qualify, finance, build or operate a facility, or win customers.
Technology and development plan
An independent March 2025 assessment found CRISLA met TRL 4 (laboratory validation), but not TRL 5 or 6. The company’s next objectives are validation in a relevant environment and testing of industrial-scale equipment. CRISLA is designed around a continuous-wave CO laser and UF₆ gas; LIS says its 1993 tests demonstrated a separation factor (β) of 6.7, versus approximately 1.25 for centrifuges. If reproducible at scale, the higher factor could reduce the number of enrichment stages. The process’s commercial performance, reliability, scalability, cost efficiency and product purity remain unproven.
| Development phase | Plan and current status |
|---|---|
| Phase 1 | Began in 2025; planned through 2027. Laboratory-scale testing and optimization aim to re-demonstrate enrichment and progress toward TRL 5. Refurbished legacy lasers were operational and ready for enrichment testing as of May 2026. |
| Phase 2 | Began in 2025; planned through 2028. Industrial-scale equipment development and testing are intended to inform scale-up and economics. LIS converted an industrial CO₂ laser to a CO laser in 2026 and is developing additional laser systems. As of the prospectus date, experimental testing of industrial-scale equipment had not yet commenced. |
| Phase 3 | Preparatory work only: licensing, environmental characterization, site preparation and conceptual design. No Phase 3 testing or facility construction had begun. A Pilot Plant is targeted for operational readiness around 2030, at approximately 50 metric tons of LEU and 0.5 million SWU annually. |
| Phase 4 | Not begun. LEU-3 commercial operations are targeted around 2033, initially at 3.0 million SWU annually, with potential expansion to 5.0 million SWU (approximately 500 metric tons of LEU). The Pilot Plant and expanded LEU-3 together would represent approximately 5.5 million SWU annually. |
These are targets, not operating capacity or committed construction plans. They depend on technical progress, financing, licensing, permits, construction, market conditions and customer demand.
LIS received a Tennessee radiological-material license in December 2025 for Phase 1/2 work. A UF₆ cylinder was delivered in October 2026, with experiments expected before year-end. The NRC approved the facility security plan in October 2026; it becomes active only after a successful operational-readiness review. The company is renovating its Oak Ridge demonstration facilities and acquired a 38,000-square-foot property in July 2026 for Phase 2 support.
The planned Pilot Plant and LEU-3 would be located on the company-owned 206-acre LIST Island brownfield site in Oak Ridge, adjacent to the historic K-25 enrichment site. LIS estimates LEU-3 capital investment of approximately $1.38 billion and has said it could create more than 200 direct jobs. NRC licenses will be required for both facilities. The company’s modular approach is intended to expand capacity by replicating laser-and-separator modules, but the benefits remain unvalidated.
Economics, funding and government programs
Management estimates combined Pilot Plant/LEU-3 capacity of approximately 5.5 million SWU annually and LEU-3 capital cost of approximately $1.37 billion. Its estimated laser-enrichment operating cost is $16.87/SWU, based on assumptions including 75% availability, electricity at $0.10/kWh, and approximately 250 employees. The filing also cites annual operating costs of approximately $92.8 million, but calculates the $16.87/SWU estimate using approximately $84.4 million divided by 5.5 million SWU—an internal inconsistency. Estimated capital cost is approximately $13/SWU, and combined operating and capital cost approximately $30/SWU. These are management estimates, not demonstrated commercial economics. The company compares them with historical centrifuge estimates of approximately $60/SWU and more recent estimates of $100–$200/SWU.
LIS says existing cash and other available capital may support a scaled, prioritized subset of Phase 1 and Phase 2 work; other discretionary activities may be deferred. Further development and especially Phases 3 and 4 require substantial additional capital. The company expects to pursue equity or debt, strategic investment, commercial arrangements and potentially government funding, but says its plan is not contingent on any specific government award.
LIS is one of six participants in a 10-year DOE IDIQ contract with a $3.4 billion shared ceiling; it is not a construction grant or committed funding. Its completed 2025 DOE report task order had a $515,000 ceiling, with $181,042 of receivables for work performed as of July 31, 2026. In January 2026, DOE awarded $900 million each to three higher-TRL companies; LIS was not among them. The company also completed a $74,866 Air Force SBIR Phase I award. Potential state, local and TVA incentives exceed $200 million over their life, but had not been received and remain conditional; they do not fund construction or operations.
Partnerships, competition and risks
NANO Nuclear invested approximately $2.0 million in LIS in August 2024 for 2,666,667 shares. Their collaboration framework contemplates NANO supplying UF₆ feedstock and LIS providing enriched and deconverted fuel, with reciprocal preferred-customer status and possible joint research and sales. No definitive commercial agreement exists; pricing, cost allocation, responsibilities and regulatory requirements remain to be negotiated, and either party may terminate the collaboration on at least 90 days’ notice.
LIS agreed to issue Starfire Industries 3.0 million shares for CRISLA laser IP and development services; all were issued in March 2026, with 750,000 vested immediately and the remainder subject to milestones through 2031. The relationship is intended to develop a domestic laser supply chain. Enveniam provides project integration and technical support for LEU-3, including licensing, procurement and design work.
Established suppliers such as Centrus Energy and Urenco have operating facilities, licensing precedents, customers and mature supply chains. Other prospective competitors include Orano, Global Laser Enrichment and General Matter. The sector also faces significant technical, capital, construction, security, maintenance and regulatory barriers; prior enrichment technologies have failed to reach commercial operation despite major investment. LIS disclosed to DOE/NNSA in September 2026 certain violations of export-controlled document requirements under 10 CFR Part 810, primarily involving document marking and IT storage or transfer. It reports taking remedial and preventive actions and had received no response as of the prospectus date.
Management
Leadership and operating expertise
Co-founder Jay Jiang Yu became CEO in August 2025, after serving as President from December 2021 through July 2025; he remains Chairman and a director. Co-founder Christo J. Liebenberg became President and Chief Technical Advisor in August 2025, after serving as CEO from September 2023 through July 2025. CFO Ewurama Rhule has held that role since January 2025, and CTO Viktor Chikan since December 2024. Lloyd Jollay became COO in February 2026, following his service as Manager of UF6 Handling Systems from July 2025 through January 2026.
The leadership team’s experience spans laser and optical systems, uranium-isotope enrichment, CRISLA process development, and nuclear fuel-cycle operations. Liebenberg has more than 30 years of laser and optical-systems experience, including prior work at Silex and ASML. Chikan has experience in laser systems, nanomaterials, and EUV research, including at ASML. Jollay brings more than 30 years in nuclear safety, materials management, and fuel-cycle operations, including leadership at Y-12 and work on highly enriched uranium supply and return, licensing support, and nuclear safety programs.
Yu also holds roles at NANO Nuclear, Human Continuum, and I Financial Ventures Group; Liebenberg has led CRISLA, Inc. These outside commitments are disclosed, without discussion of their effects on time allocation or related-party arrangements.
Board, committees, and risk oversight
The company has four directors: one executive and three independent directors—Atul Sabharwal, Jason S. Mencher, and Eric Forte. Mencher and Forte joined the board in October 2026. The CEO also serves as board chair; the company considers this structure appropriate. Sabharwal’s experience includes technology, digital media, and business development; Mencher’s includes environmental review, land-use, and real-estate law; and Forte’s includes mortgage brokerage and financial services.
All three independent directors serve on the Audit, Compensation, and Nominating and Corporate Governance Committees. Sabharwal chairs the Audit and Compensation Committees and is the audit committee financial expert; Mencher chairs the Nominating and Corporate Governance Committee. The company has adopted an executive compensation clawback policy for material financial-reporting noncompliance requiring an accounting restatement. No compensation-committee interlocks are reported, and no committee member is or has been a company officer or employee.
Management identifies and manages risks, with oversight by the full board and its committees. Oversight is conducted through committee-chair and responsible-officer reports and regular communication with management. The company plans to adopt a written code of business conduct and ethics on or before completion of the offering and post it on its website; specified amendments or waivers will be disclosed on its website or in SEC filings.
Advisory board and compensation arrangements
The Executive Advisory Board brings expertise in uranium and laser enrichment, fuel-cycle operations and manufacturing, advanced reactors, isotope production, nuclear security, international nuclear cooperation, and energy policy. Its stated role is to help assess markets and applications for LIST technology; identify potential partners, customers, research institutions, and funding; advise on commercialization, licensing, safety, safeguards, and policy; and facilitate government, industry, and stakeholder relationships. These are advisory responsibilities, not evidence of completed partnerships, approvals, or commercialization milestones.
Members include former senior U.S. military leaders, former Congressman John Shimkus, and former NNSA and national-laboratory leaders. Junaid Razvi became Senior Advisor in Nuclear Energy and Dennis Garratt became Chairman of the Executive Advisory Board for Laser Enrichment (CRISLA 2G Canada) in May 2024; Tom Blees has served as Head of Corporate Initiatives since June 2023. Randall Beatty became chair of the UF6 Gas Handling Systems advisory board in April 2026. Their backgrounds include national-laboratory and international nuclear work, reactor operations and fuel manufacturing, nuclear policy, and uranium-processing and fluorine-chemistry patents.
Advisory-board members are independent contractors, not employees, and may pursue other engagements. Agreements generally provide cash compensation, confidentiality and other customary restrictive covenants, and terms of 12–48 months; they may be terminated early. Brent Park and Lieutenant General Hinote have analogous arrangements through their respective entities. Compensation paid to board members was $311,000 as of October 31, 2026, versus $248,000 as of October 31, 2025.
Equity compensation includes 125,000 vested options for John M. Paxton Jr. and 75,000 for John M. Shimkus, each at a $0.75 exercise price and fully vested on grant; they expire August 13, 2028 and August 1, 2028, respectively. Brent Park, through One Step Removed, LLC, received 50,000 vested options on November 10, 2025, at a $3.00 exercise price, expiring November 10, 2031; the grant was outside the 2023 and 2026 plans and relied on the Securities Act Section 4(a)(2) exemption. Shares issued for services were: Beatty, 200,000 at $0.30 per share; Razvi, 40,000 at $0.75; Garratt, 30,000 at $0.75; and Blees, 80,000 at $0.13. On October 14, 2026, the board approved 50,000 RSUs for Beatty, vesting in three equal annual installments beginning on the first anniversary.
Legal matters
To the company’s knowledge, directors and executive officers have had none of the specified disqualifying legal or regulatory proceedings in the prior ten years. The company may face ordinary-course legal or administrative claims; proceedings could impose substantial costs and divert company resources, including management time, regardless of outcome.
Executive and director compensation
Executive compensation
Named executive officer compensation increased in FY2026, driven mainly by higher reported option-award values and salaries. The option-award amounts are grant-date fair values, not cash paid. The filing also says no options were granted to named executive officers during FY2026, creating a disclosure inconsistency.
| Compensation | FY2026 | FY2025 |
|---|---|---|
| Total for named executive officers | $5.8983M | $3.9427M |
| Salary | $1.5792M | $1.1150M |
| Option awards | $4.3191M | $2.4986M |
| Bonus and all other compensation | $0 | $329,081 |
| Executive | FY2026 total compensation | FY2025 total compensation |
|---|---|---|
| CEO Jay Jiang Yu | $3.7306M | $2.6897M |
| President Christo Liebenberg | $1.0213M | $804,233 |
| CFO Ewurama Rhule | $286,896 | $150,201 |
| CTO Viktor Chikan | $310,014 | $211,862 |
| COO Lloyd Jollay | $549,551 | $86,667 |
FY2025’s bonus and other compensation included a $120,000 bonus to Yu and $209,081 of all-other compensation across the executives. Salaries rose for all five executives.
On October 14, 2026, executives received 2.03M RSUs under the 2026 Plan: Yu 1.38M; Liebenberg 250,000; Chikan and Jollay 150,000 each; and Rhule 100,000. Each RSU represents one common share; one-third vests on each of the first three grant anniversaries, subject to continued service.
Yu held 15.4M fully vested options issued outside company option plans through I Financial, which he solely owns: 7.4M at $0.75, 4.0M at $0.75, 2.0M at $1.80, and 2.0M at $3.00. Other executives held 2.36M fully vested options under the terminated 2023 Plan: Liebenberg 2.005M, Rhule 125,000, Chikan 50,000, and Jollay 180,000. Their exercise prices range from $0.75 to $3.00 per share. Outstanding options remain in effect despite the 2023 Plan’s termination; these options and the new RSUs represent potential dilution.
Director compensation and awards
Independent directors generally receive cash and equity under agreements typically lasting two years, terminable by either party at any time; equity vesting generally depends on continued board service. Executive directors receive no additional board compensation.
| Director stock-award compensation | FY2026 | FY2025 |
|---|---|---|
| Michele A. Perlin | $160,862 | $184,214 |
| Kerry Sebree | $40,215 | $146,979 |
Other listed directors had no reported compensation in the table for either year, and no director stock-option awards were reported for FY2026 or FY2025. On October 14, 2026, three non-executive directors received 50,000 RSUs each (150,000 total), vesting one-third on each of the next three grant anniversaries subject to continued service. Perlin and Sebree resigned five days after the grant, on October 19. Atul Sabharwal exercised 75,000 options in March 2026 and received 75,000 shares. No common shares were issued as equity awards to executive officers or directors during FY2026 or FY2025.
2026 Equity Incentive Plan
The plan initially reserves 6,098,711 shares: 3,000,000 new shares plus 3,098,711 shares available under the 2023 Plan when the new plan takes effect. From January 1, 2028 through January 1, 2036, the reserve increases annually by the lesser of 5% of prior year-end shares outstanding or a smaller amount set by the board or committee. Up to 10,000,000 shares may be issued as incentive stock options. These are plan limits, not amounts already granted or issued. Certain unused or forfeited award shares can return to the general reserve, but not the incentive-option reserve.
The plan authorizes options, stock appreciation rights, restricted stock and units, performance and other stock- or cash-based awards for eligible directors, employees, and consultants; incentive options are limited to employees. Administrators have broad discretion over award terms, vesting, acceleration, and performance goals. Options and SARs generally require an exercise price at least equal to grant-date fair market value (110% for incentive options to 10%-or-greater shareholders); terms are capped at 10 years, or five years for those incentive options. Non-employee director awards and other cash compensation are capped at $1.0M in a director’s first calendar year and $750,000 in each later year. Repricing options or SARs requires shareholder approval, and awards are subject to company clawback policies.
On a change in control, awards generally are assumed or replaced by the successor. If they are not, and the administrator makes no alternative determination, awards fully vest, restrictions lapse, and performance awards are treated as achieved at target. The plan lasts 10 years unless ended earlier. The company intends to register issuable shares on Form S-8.
Agreements and tax considerations
Yu, Liebenberg, and Chikan’s employment agreements began December 1, 2024, have initial three-year terms with automatic one-year renewals, and provide base salary plus discretionary bonuses. Liebenberg and Chikan are expected to work about 40 hours weekly; Yu’s commitment is based on what is reasonably required. Rhule and Jollay have at-will agreements providing base salary and benefits, with approximately 40-hour workweeks. All agreements permit termination at will subject to applicable notice and earned-compensation terms; the company sponsors no executive retirement arrangements.
Most awards generally create ordinary income for participants and a corresponding company tax deduction when exercised, vested, or paid, as applicable. Change-in-control acceleration may trigger parachute-payment treatment, potentially eliminating the company deduction and imposing a 20% federal excise tax on recipients. Noncompliant RSUs may trigger immediate ordinary income tax upon vesting, plus a 20% federal tax and premium interest.
Principal stockholders
Principal stockholders and IPO ownership
The ownership information is presented around the IPO. As of November 13, 2026, 71.7114 million common shares were outstanding, including 2.250 million shares issued to Starfire Industries that are subject to performance milestones and may be forfeited and cancelled if the milestones are not met. Assuming no underwriters’ over-allotment, the post-offering share count is 74.8114 million, an increase of 3.100 million shares.
| Holder | Beneficial shares | Before offering | After offering |
|---|---|---|---|
| Jay Jiang Yu, CEO and Chairman | 21.8000M | 25.92% | 25.00% |
| I Financial Ventures Group LLC | 20.2000M | 24.02% | 23.16% |
| Christo J. Liebenberg, President | 4.4050M | 5.98% | 5.73% |
| All eight directors and executive officers as a group | 26.9939M | 31.22% | 30.14% |
Beneficial-ownership percentages include options exercisable within 60 days in the relevant holder’s numerator; those option shares are not included in the denominator used for other holders. Yu’s reported beneficial ownership includes 12.4000 million shares issuable to I Financial upon exercise of vested options. I Financial’s reported ownership includes 7.8000 million shares held of record, of which 3.0000 million resulted from an October 2026 option exercise. Yu has voting and dispositive power over I Financial’s shares, so the reported Yu and I Financial amounts overlap and should not be added together.
Liebenberg’s beneficial ownership includes 2.0050 million shares issuable upon exercise of vested options. The CEO and President each indicated interest in purchasing up to $250,000 of shares in the offering at the IPO price and on the same terms as other purchasers; the ownership table assumes neither participates.
Recent equity awards
On October 14, 2026, the company granted restricted stock units under its 2026 Plan to the CEO (1.380 million), the President (250,000), and other named executives and directors (100,000 to 150,000 each); independent director Atul Sabharwal received 50,000. Each award vests in equal one-third annual installments over three years, subject to continued service. These grants are separate from the beneficial-share figures above.
Description of capital stock
Capital stock and share issuance
As of November 13, 2026, 71,711,408 common shares were outstanding, including 2,250,000 shares issued to Starfire Industries subject to performance-based vesting and forfeiture if specified milestones are not met on time. No preferred shares were outstanding. The company was authorized to issue 275,000,000 common shares and 25,000,000 preferred shares; par value is $0.0001 per share.
A 1-for-2.5 reverse stock split took effect April 22, 2024, with share and per-share amounts retroactively adjusted. At that time authorized common shares were reduced from 200,000,000 to 80,000,000. On June 15, 2024, common authorization increased to 275,000,000 and preferred authorization decreased from 100,000,000 to 25,000,000, leaving total authorized shares unchanged.
The company issued shares in private transactions exempt from registration under Securities Act Section 4(a)(2), Regulation S, Rule 144A or Rule 701. Significant issuances included:
| Period | Issuances and proceeds |
|---|---|
| 2022 | Issued 4.0M shares to I Financial, wholly owned by CEO and Chairman Jay Jiang Yu; separately issued 2.600001M shares for services to Yu and Jaisun Garcha, a consultant who also serves as CFO of related party NANO Nuclear. |
| 2023 | Sold 4.929663M shares for C$246,483 in March and 5.491392M shares for C$686,424 in August. Issued 4.8M shares to former CRISLA shareholders at closing, with a further 3.2M shares contingent on four milestones (800,000 per milestone). Service issuances included 800,000 shares to James Walker, CEO and a director of NANO Nuclear, and 80,000 to advisory board member Thomas Blees. |
| 2024 | Raised $34.4458365M: 1.740756M shares for $1.305567M in March; 2.666667M shares sold to NANO Nuclear for $2.0M and 11.425178M sold to investors for $8.5688835M in August; and 12.539646M sold to investors for $22.571386M in December. Additional shares were issued for consulting and advisory services, including 250,000 to CTO Viktor Chikan. |
| 2025 | Sold 3.976764M shares for $11.930292M in May. |
| 2026 | Raised $24.226692M from sales of 285,714 shares to a Titan affiliate for $1.0M and 4.599682M shares to investors for $16.098912M in January, and 1.781945M shares to investors for $7.12778M in March. |
In March 2026, the company issued 2.039M shares upon option exercises: 800,000 exercised through CEO-controlled I Financial, 550,000 by related-party consultant Garcha, 300,000 by Walker, 160,000 by Udyr Tech LLC (controlled by the CEO’s sibling), 75,000 by independent director Atul Sabharwal, and 154,000 to other consultants. The company also issued 3.0M shares to Starfire Industries in March under a strategic investment agreement, subject to forfeiture conditions. Further option exercises resulted in 30,000 shares issued in July, 300,000 in September, 3.0M to I Financial in October, and 100,000 in November.
Potential dilution and trading restrictions
Outstanding options at November 13, 2026 covered 6,168,007 shares under the 2023 Stock Option Plan and 17,672,000 shares outside that plan. Outstanding RSUs covered 5,115,000 shares under the 2026 Plan, with another 983,711 shares reserved for future RSU grants; no options had been granted under the 2026 Plan as of the prospectus date. Upon offering close, the company agreed to issue the underwriters’ representative a warrant for up to 217,000 shares, exercisable at $6.90 per share (115% of the assumed $6.00 IPO price), from the first day of the seventh month after closing through the fifth anniversary.
Directors, officers and affiliates are subject to a 180-day lock-up. During that period, the company is also restricted from specified equity and debt offerings and transfers without underwriter consent, subject to exceptions. Certain non-insider holders owning at least 0.5% may sell in staged leak-outs: 25% after 90 days, another 25% after 120 days and the remaining 50% after 180 days.
Governance and listing considerations
Common shareholders have one vote per share, no cumulative voting rights, and ratable dividend and liquidation rights subject to any preferred-stock priorities. A quorum generally requires one-third of voting common shares. The board may issue preferred stock in series without stockholder approval and establish its voting, dividend, conversion, redemption and liquidation rights; it may also issue authorized common shares without approval for financing, acquisitions or employee plans. These powers offer flexibility but could dilute existing holders or impede a change of control.
Nevada law regulates combinations with interested stockholders owning 10% or more for three years, subject to exceptions; the company opted out of Nevada’s control-share acquisition provisions. Director removal generally requires two-thirds of voting power, remaining directors may fill board vacancies, and advance-notice requirements apply to stockholder proposals and nominations. Together, these provisions may make replacing directors or changing control more difficult and could deter or delay takeover proposals. Nasdaq listing is not assured: the company applied to list under “LIS,” and closing the offering is conditioned on final Nasdaq approval.
Material u s federal income tax conseq uences to
U.S. federal income tax consequences to non-U.S. holders
The company has never declared or paid cash dividends. If it makes distributions, amounts paid from current or accumulated earnings and profits generally will be treated as dividends. Any amount exceeding earnings and profits first reduces the holder’s tax basis, but not below zero; any remaining excess is treated as capital gain.
Dividends
Dividends paid to non-U.S. holders generally are subject to 30% U.S. withholding tax on the gross amount, unless an applicable income tax treaty provides a lower rate and the holder properly documents eligibility. Dividends effectively connected with a U.S. trade or business generally are exempt from this withholding if the holder provides the required IRS form, but are instead taxed at graduated U.S. rates. A corporate holder may also owe a 30% branch profits tax, potentially reduced by treaty.
Dispositions of stock
Non-U.S. holders generally are not subject to U.S. federal income tax on gains from selling the stock, except when:
- The gain is effectively connected with the holder’s U.S. trade or business. Such gains are taxed at graduated rates, and corporate holders may also face branch profits tax.
- An individual holder is present in the United States for at least 183 days in the relevant tax year and meets other conditions. This exception generally imposes 30% tax, or a lower treaty rate, with potential offsets for qualifying U.S.-source capital losses.
- The stock is treated as a U.S. real property interest because the company is a U.S. real property holding corporation (USRPHC).
The company believes it is not, and will not become, a USRPHC, but gives no assurance. USRPHC status depends on the relative fair market values of U.S. real property, worldwide real property, and other business assets. If the stock is regularly traded and the company becomes a USRPHC, a holder generally is subject to this rule only if the holder actually or constructively owns more than 5% of the stock during the shorter of the five-year period before the disposition or the holder’s holding period.
Withholding and reporting
Dividends may also be subject to 24% backup withholding. Backup withholding is not an additional tax and may be credited against or refunded with the holder’s tax liability. Proper IRS Form W-8 documentation generally establishes an exemption. Applicable reporting and withholding treatment can depend on the payment intermediary and where the transaction occurs.
FATCA generally imposes 30% withholding on dividends paid to non-compliant foreign financial institutions and to certain non-financial foreign entities that fail to meet reporting, ownership-disclosure, or exemption requirements. FATCA withholding may apply even when a treaty or another exemption would otherwise apply. Proposed regulations eliminate FATCA withholding on gross proceeds, but remain subject to change; intergovernmental agreements may modify the requirements.
Scope and uncertainty
This discussion covers only specified U.S. federal income tax consequences. It does not address many state, local, foreign, gift, estate, or special-investor rules, and excludes, among others, certain financial institutions, tax-exempt entities, partnerships and their investors, holders of more than 5% except as specifically addressed, and holders who own stock through hedges or as compensation. Tax authorities or courts may disagree with the company’s interpretation, and tax laws or guidance may change, potentially retroactively. The company has not sought an IRS ruling.
Underwriting
Underwriting and offering terms
The assumed IPO price is $6.00 per share. The 465,000-share over-allotment option represents 15% of the base offering, implying 3.10 million base shares and up to 3.565 million shares if fully exercised.
| Offering scenario | Shares | Gross proceeds | Estimated net proceeds |
|---|---|---|---|
| Base offering | 3.10 million | $18.6 million | — |
| Full over-allotment exercise | 3.565 million | $21.39 million | Approximately $19.0 million |
Titan’s underwriting discount is 6.5% of gross proceeds, with an additional non-accountable allowance of 1.15% of gross proceeds. Estimated other offering expenses are approximately $767,786, excluding the discount and allowance. The company advanced the underwriters $20,000 against accountable expenses and agreed to reimburse reasonable out-of-pocket expenses up to $200,000 ($150,000 for legal and $50,000 for non-legal expenses). If the offering does not close, reimbursement is capped at $50,000 for documented expenses.
Titan will receive warrants to purchase 217,000 shares, equal to 7% of the base offering, at $6.90 per share (115% of the assumed IPO price). The warrants are exercisable from the first day of the seventh month after closing through the fifth anniversary, carry five years of piggyback registration rights if the underlying shares are not registered, and are subject to a 180-day transfer and hedging restriction.
For 12 months after closing, Titan may also receive compensation on qualifying subsequent financings from investors it introduced, provided it documents that it first contacted them for the company. Compensation would include a 6.5% underwriting discount, warrants covering 7% of securities issued, and expenses. This arrangement does not apply if the IPO is not completed and may be terminated for cause.
Insider participation and transfer restrictions
An affiliate of Titan subscribed for 285,714 shares for approximately $1.0 million in a private placement issued January 12, 2026. CEO and chair Jay Jiang Yu and President and co-founder Christo J. Liebenberg each indicated nonbinding interest in purchasing up to $250,000 of IPO shares; any purchases would reduce the shares available to public investors. Insider IPO shares are subject to a 180-day lock-up and resale restrictions.
The company, its directors and officers, and their affiliates are generally subject to lock-ups restricting transfers and certain debt offerings, subject to exceptions and Titan’s consent. Existing holders with at least 0.5% ownership who are not insiders may sell 25% of their holdings after 90 days, another 25% after 120 days, and the remaining 50% after 180 days.
Listing and market considerations
No public market for the shares existed before the offering. Nasdaq approval is a closing condition; failure to meet initial listing criteria or obtain approval would prevent the offering from closing. The company and underwriters do not assure that an active market will develop or that shares will trade at or above the IPO price. Underwriters may conduct stabilization, short-covering, penalty-bid, and passive market-making transactions that could affect the share price.
The underwriters may receive customary fees for future services. The company does not expect to retain them for other investment-banking services for at least 90 days after the prospectus date; they provided no such services during the preceding 180 days apart from the offering.
Selling restrictions
The securities are generally unregistered and are not approved for public sale in the jurisdictions described. Offers and resales are restricted to eligible investors or transactions qualifying for local exemptions. Restrictions include limits to accredited investors and permitted clients in Canada; qualified institutional investors in Japan; qualified or otherwise exempt investors in several European countries and the UK; and restrictions on public offers in the Cayman Islands, Switzerland, Israel, the UAE and DIFC. Australia imposes a general 12-month resale restriction unless permitted by law. Local securities, prospectus, marketing, and resale requirements also apply in the relevant jurisdictions; noncompliant Italian transfers may be void and expose transferors to damages liability.
Legal matters
Legal Matters
Parsons Behle & Latimer of Reno, Nevada, will pass upon the validity of LIS’s common stock issuance in the offering. Ellenoff Grossman & Schole LLP of New York, New York, will handle certain other legal matters for LIS. Lucosky Brookman LLP of Woodbridge, New Jersey, represents the underwriters.
Experts
WithumSmith+Brown, PC audited LIS’s consolidated balance sheets as of October 31, 2025 and 2024, and its consolidated statements of operations, stockholders’ equity, and cash flows for the fiscal years ended October 31, 2025 and 2024. The auditor’s report is dated June 22, 2026, and the filing includes the financial statements in reliance on that report.
Where you can find additional information
Additional Information
LIS has filed an S-1 registration statement, but the prospectus is not complete. Descriptions of contracts and other documents are qualified by the exhibits filed with the registration statement; investors should review those exhibits for the documents’ full terms.
LIS does not currently file periodic reports with the SEC. Upon completion of the offering, it will be required to file periodic reports, proxy statements, and other information under the Exchange Act. After the offering, these materials are expected to be available free of charge on the company’s website as soon as reasonably practicable after they are filed with or furnished to the SEC. The website’s contents are not part of, and are not incorporated into, the prospectus.
Financial statements
LIS Technologies Inc. — Financial statements and notes
Business and results
LIS is a pre-revenue developer of patented laser isotope-separation technology, including planned applications in LEU, HALEU, medical and scientific isotopes, and semiconductor and quantum-computing markets. Commercial revenue depends on successful technology development, licensing and commercialization. LIS reported one operating segment.
| Results | Q3 FY2026 | Q3 FY2025 | 9M FY2026 | 9M FY2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating loss | $(4.519)M | $(3.069)M | $(27.229)M | $(12.138)M |
| Net loss | $(4.299)M | $(6.373)M | $(29.688)M | $(18.248)M |
| Diluted loss per share | $(0.07) | $(0.11) | $(0.47) | $(0.35) |
For the nine months, general and administrative expense increased to $15.783M from $9.560M, and research and development expense increased to $11.446M from $2.578M. The prior-year periods included fair-value changes in CRISLA acquisition consideration: $3.840M in Q3 and $7.200M for 9M, compared with no Q3 FY2026 change and a $3.200M increase in the payable for 9M FY2026. Interest income was $220,361 in Q3 FY2026 versus $355,452, and $740,808 for 9M versus $834,520. Prior-year 9M other income also included $181,042 from a U.S. Department of Energy task order and $74,866 from a U.S. Air Force SBIR award.
Cash flows and balance sheet
| Cash flow | 9M FY2026 | 9M FY2025 |
|---|---|---|
| Operating cash outflow | $(14.819)M | $(5.424)M |
| PP&E purchases (capital expenditures) | $(24.876)M | $(1.075)M |
Financing provided $25.258M in 9M FY2026. The company reported $24.227M from common-stock issuances and $1.179M from option exercises. Cash declined by $14.438M during the nine months.
| Balance-sheet item | July 31, 2026 | October 31, 2025 |
|---|---|---|
| Total assets | $50.919M | $37.746M |
| Total stockholders’ equity | $32.356M | $26.164M |
| Cash | $18.792M | $33.229M |
| PP&E, net | $28.989M | $2.0258M |
| Goodwill | $0 | $0 |
| IPR&D intangible asset (excluding goodwill) | $1.6795M | $1.241M |
| Acquisition consideration payable in equity | $12.800M | $9.600M |
PP&E investment includes LIST Island land of $8.0117M; land at 150 Americus Avenue of $246,819; a building there of $5.9287M; $3.7606M of construction in progress at 203 Victorius; and $11.041M of construction in progress for the LEU-3 Facility. LIS acquired the Oak Ridge land and building on July 27 for $6.160M in cash, with no financing; the property was recorded at $6.1755M including acquisition costs and closing credits. In January 2026, it acquired LIST Island land and began capitalizing pre-construction, design and development costs for LEU-3. Physical construction had not begun by July 31. No depreciation was recorded because no depreciable assets were in service.
Liquidity, financing and shares
LIS had an accumulated deficit of $65.419M, recurring losses and negative operating cash flows. Under its current plan, including planned capital expenditures, cash was expected to fund operations only into Q1 FY2027. Management said additional capital would be needed and that equity, debt, strategic investment or commercial arrangements were possible but not assured on acceptable terms. It concluded substantial doubt about going concern was alleviated based on the ability to defer or sequence discretionary spending, including facility development and a substantial portion of planned CRISLA laboratory work. Cash held at a financial institution exceeded federally insured limits.
| Common shares outstanding | Shares |
|---|---|
| October 31, 2025 | 56.575M |
| July 31, 2026 | 68.311M |
The July total includes 2.250M legally issued vendor shares subject to milestones and forfeiture; they were excluded from accounting shares and basic EPS until vesting. Nine-month equity-based compensation was $10.475M ($5.453M in G&A and $5.022M in R&D), versus $5.347M ($4.857M and $0.490M). The current-period R&D amount included $3.000M for 750,000 vendor shares that vested; no cost was recognized for the additional 2.250M performance-based shares because achievement was not considered probable.
| Anti-dilutive securities excluded from diluted loss per share | July 31, 2026 | July 31, 2025 |
|---|---|---|
| Options | 27.290M | — |
| Vendor performance-based shares | 2.250M | — |
| CRISLA contingent consideration shares | 3.200M | — |
| Total | 32.740M | 27.912M |
Outstanding options had a $1.32 weighted-average exercise price, a 7.89-year weighted-average contractual term and $20.496M aggregate intrinsic value. LIS issued 4.647M fully vested options in the quarter ended January 31, 2026, valued at $7.475M; none were issued in Q3. It exercised 2.069M options for $1.179M during the nine months. After the period, CEO and Chairman Jay Jiang Yu exercised 3.0M options at $0.75 per share through his wholly owned entity, generating approximately $2.25M. On October 14, LIS granted 3.425M RSUs vesting in equal thirds over three years and 1.690M vesting in equal sixths over six years, subject to continued service.
LIS raised $17.099M from a Series B sale of 4.885M shares at $3.50 in the quarter ended January 31, 2026, and $7.128M from a March 2026 Series C sale of 1.782M shares at $4.00. Deferred IPO offering costs were $148,004 at July 31; they will be charged against proceeds if an offering is completed, or expensed if it is abandoned or postponed more than 90 days.
CRISLA acquisition and other notes
The August 2023 CRISLA asset acquisition allocated $1.241M of its $1.245M purchase consideration to acquired IPR&D. LIS expects all four milestones to be achieved, triggering 3.200M contingent shares. After the fourth milestone, former shareholders may also receive up to $10M in cash, reduced by the fair value of shares issued. Management expects the closing and contingent shares together to exceed $10M and therefore expects no additional cash payment. The contingent-share valuation uses LIS’s common-stock price from third-party cash sales as of March 26, 2026. Former shareholders are entitled to royalties of 5% of annual net sales, recorded as operating expense when earned. The acquired IPR&D is indefinite-lived while under development, is not amortized, and had no reported impairment indicators. Finalized tax returns resulted in a $438,946 increase to IPR&D and a related deferred tax liability, plus an approximately $2.6M decrease in deferred tax assets and their valuation allowance, with no income-statement impact.
Related-party arrangements included monthly office and lab rent of $7,000 from NANO Nuclear Energy Inc., which shares a founder, officer and significant shareholder with LIS; rent expense was $21,000 for Q3 and $63,000 for 9M, all paid. Consulting fees to co-founder Dr. Jeff W. Eerkens and Udyr Tech LLC were each $30,000 for Q3 and $90,000 for 9M, all paid. NANO previously bought 2.667M LIS shares for $2.000M in August 2024.
Financial statements
LIS Technologies Inc. — FY2025 financial statements
LIS is developing patented laser isotope-separation technology for low-enriched uranium, advanced reactors, medical and research isotopes, and semiconductor and quantum-computing applications. It reported no revenue in FY2025 or FY2024, consistent with its development-stage operations.
Results
| ($M, except per-share data and shares) | FY2025 | FY2024 |
|---|---|---|
| Revenue | None | None |
| General and administrative expense | $11.878 | $10.219 |
| Research and development expense | $3.874 | $1.424 |
| Operating loss | $(15.752) | $(11.643) |
| Other income | $1.412 | $0.064 |
| Fair-value charge on acquisition consideration payable in equity | $7.200 | $2.102 |
| Net loss | $(21.539) | $(13.681) |
| Basic and diluted loss per share | $(0.40) | $(0.50) |
| Weighted-average basic and diluted shares (M) | 53.306 | 27.619 |
Operating loss widened 35.3%, with R&D expense rising 172% as development spending increased. Net loss widened 57.4%, including the $7.200M noncash remeasurement charge on the CRISLA acquisition consideration. Other income included $1.157M of interest income, $181,042 from a U.S. Department of Energy Task Order, and a $74,866 Small Business Innovation Research award; FY2024 interest income was $64,157.
Cash flow and funding
| ($M) | FY2025 | FY2024 |
|---|---|---|
| Operating cash flow | $(8.345) | $(3.198) |
| Capital expenditures (property, plant and equipment purchases) | $(1.822) | $(0.204) |
| Financing proceeds | $26.767 | $19.599 |
| Increase in cash | $16.600 | $16.197 |
| Ending cash | $33.229 | $16.630 |
FY2025 financing proceeds came from common-stock issuances. The company raised $11.930M through a Series A financing (3.977M shares at $3.00). The Angel Round issued 12.540M shares at $1.80 for $22.571M; $7.735M of subscriptions had been received by October 31, 2024, with a further $14.836M received in November–December 2024. FY2024 Seed Round proceeds were $11.874M from 15.833M shares at $0.75.
Balance sheet and liquidity
| ($M) | October 31, 2025 | October 31, 2024 |
|---|---|---|
| Total assets | $37.746 | $18.648 |
| Total liabilities | $11.583 | $3.059 |
| Total stockholders’ equity | $26.164 | $15.589 |
| Cash | $33.229 | $16.630 |
| Goodwill | None | None |
| Intangible assets other than goodwill: in-process R&D | $1.241 | $1.241 |
| Property, plant and equipment / construction in progress | $2.026 | $0.204 |
| Acquisition consideration payable in equity | $9.600 | $2.400 |
Working capital was $32.454M, while the accumulated deficit was $35.731M. Management expects working capital to fund obligations for at least 12 months after issuance of the statements, but longer-term plans depend on additional equity contributions and, ultimately, profitable operations. Cash deposits exceeded federally insured limits in both years. The $1.241M in-process R&D asset is not amortized while in development; management reported no impairment indicators and supported capitalization based on identified alternative future uses. Construction in progress increased substantially, and no depreciation was recorded because no depreciable assets had been placed in service.
Shares, equity compensation and acquisition obligation
| Common shares outstanding (M) | FY2025 | FY2024 |
|---|---|---|
| Start of year | 40.059 | 23.221 |
| Issued during year | 16.516 | 16.838 |
| End of year | 56.575 | 40.059 |
Stock-based compensation was $5.347M in FY2025 ($4.857M in G&A and $0.490M in R&D), down from $8.794M in FY2024 ($7.739M in G&A and $1.056M in R&D). FY2025 grants were 5.457M fully vested options, valued at $5.347M, with a $1.80 exercise price and $0.98 weighted-average grant-date fair value; FY2024 grants were 19.255M options valued at $8.041M. At year-end, 24.712M options were outstanding, vested and exercisable (19.255M a year earlier), with a $0.94 weighted-average exercise price, an 8.65-year weighted-average contractual term and $13.388M aggregate intrinsic value. All were excluded from FY2025 diluted per-share calculations as anti-dilutive due to the net loss.
The August 2023 CRISLA acquisition was accounted for as an asset acquisition, with $1.245M of consideration allocated principally to in-process R&D. The company expects to issue 3.2M contingent shares on completion of four milestones. Their fair value increased from $2.400M to $9.600M, generating the FY2025 noncash charge shown above. After the fourth milestone, the agreement may require up to $10M in cash, less the fair value of shares issued; management estimates no additional cash payment if the shares’ future value meets the $10M threshold. Former CRISLA shareholders are also entitled to royalties of 5% of annual net sales, expensed when earned. The fair value estimate is Level 3 and depends on unobservable inputs, including milestone probabilities and management assumptions.
Taxes, related parties and subsequent events
Income tax expense was zero in both years because valuation allowances offset deferred tax benefits. Gross deferred tax assets were $11.829M at October 31, 2025, versus $4.834M a year earlier; the valuation allowance was $11.619M versus $4.625M. The company reported approximately $11.6M of federal, $13.7M of state and $15.6M of city NOL carryforwards. Federal NOL use is generally limited to 80% of taxable income and may also be restricted by ownership changes; state and city NOLs expire from 2039 to 2046.
Related party NANO Nuclear Energy purchased 2.667M shares for $2.000M in August 2024. LIS leased Oak Ridge office and laboratory space from NANO and paid $105,000 in FY2025.
After year-end, LIS granted 4.647M fully vested options in November 2025 at a $3.00 exercise price. It issued 4.885M shares at $3.50 for $17.099M in January 2026 and 1.782M shares at $4.00 for $7.128M in March 2026. It also issued 3.000M vendor shares in March: 750,000 vested immediately and 2.250M were subject to milestone-based vesting and forfeiture.
LIS reported one operating segment. The auditor gave an unqualified opinion on the financial statements; it was not engaged to audit internal control over financial reporting and expressed no opinion on control effectiveness.